Identification of the most active interleukin‐32 isoform
Open Access
- 2 March 2009
- journal article
- Published by Wiley in Immunology
- Vol. 126 (4) , 535-542
- https://doi.org/10.1111/j.1365-2567.2008.02917.x
Abstract
Summary: Cytokines are crucial in host defence against pathogens such as bacteria, viruses, fungi and parasites. A newly described cytokine, interleukin‐32 (IL‐32), induces various proinflammatory cytokines (tumour necrosis factor‐α, IL‐1β, IL‐6) and chemokines in both human and mouse cells through the nuclear factor‐κB and p38 mitogen‐activated protein kinase inflammatory signal pathway. The IL‐32 primarily acts on monocytic cells rather than T cells. In an attempt to isolate the IL‐32 soluble receptor, we used an IL‐32 ligand‐affinity column to purify neutrophil proteinase 3, which is a serine proteinase involved in many inflammatory diseases. IL‐32 has biological activity associated with Mycobacterium tuberculosis and chronic proinflammatory diseases such as rheumatoid arthritis. IL‐32 is transcribed as six alternative splice variants and the biological activity of each individual isoform remains unknown. Here, we cloned the complementary DNA of the four IL‐32 isoforms (α, β, γ and δ) that are the most representative IL‐32 transcripts. To produce recombinant protein with a high yield, the amino acids of two cysteine residues were mutated to serine residues, because serine residues are not conserved among different species. The multi‐step purified recombinant IL‐32 isoform proteins were assessed for their biological activities with different cytokine assays. The γ isoform of IL‐32 was the most active, although all isoforms were biologically active. The present study will provide a specific target to neutralize endogenous IL‐32, which may contribute to basic and clinical immunology.Keywords
This publication has 28 references indexed in Scilit:
- Interleukin-18 as a potential therapeutic target in chronic autoimmune/inflammatory conditionsExpert Opinion on Biological Therapy, 2006
- Involvement of IL-32 in activation-induced cell death in T cellsInternational Immunology, 2006
- Infliximab for the treatment of early rheumatoid arthritisExpert Opinion on Biological Therapy, 2005
- Nod2-Dependent Regulation of Innate and Adaptive Immunity in the Intestinal TractScience, 2005
- Wegener granulomatosis in childhood and adolescenceEuropean Journal of Pediatrics, 2004
- Generation of highly stable IL-18 based on a ligand–receptor complex structureBiochemical and Biophysical Research Communications, 2004
- Single and combined inhibition of tumor necrosis factor, interleukin‐1, and RANKL pathways in tumor necrosis factor–induced arthritis: Effects on synovial inflammation, bone erosion, and cartilage destructionArthritis & Rheumatism, 2004
- Identification of Amino Acid Residues Critical for Biological Activity in Human Interleukin-18Published by Elsevier ,2002
- TNF, Apoptosis and Autoimmunity: A Common Thread?Blood Cells, Molecules, and Diseases, 1998
- Mapping of a susceptibility locus for Crohn's disease on chromosome 16Nature, 1996